Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.68 |
| ▸ | CHUK | O15111 | 4/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | BTK | Q06187 | 2/20 | 0.68 |
| ▸ | ITK | Q08881 | 2/20 | 0.68 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.68 |
| ▸ | ADK | P55263 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658857 | 0.94 | IKBKB (0.71) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659274 | 0.89 | IKBKB (0.72) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658019 | 0.87 | IKBKB (0.73) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659550 | 0.86 | IKBKB (0.72) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658626 | 0.85 | IKBKB (0.77) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658660 | 0.84 | IKBKB (0.63) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5666341 | 0.84 | IKBKB (0.62) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5658955 | 0.84 | IKBKB (0.62) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5655431 | 0.83 | CDK2 (0.73) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL5659228 | 0.83 | IKBKB (0.67) | IKBKBCHUKCDK2BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | claimed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | claimed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | disclosed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | IKBKB 243/4885CHUK 197/4885CDK2 350/4885 |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | IKBKB 151/4885CHUK 272/4885CDK2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.